DTIL
Precision
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DTIL Profile
Precision Biosciences, Inc.
A clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies
Biological Technology
Invalid Date
03/28/2019
NASDAQ Stock Exchange
108
12-31
Common stock
302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701
--
Precision BioSciences, Inc., is incorporated in Delaware. The company is an advanced gene editing company that utilizes the novel proprietary ARCUS platform to develop in vivo gene editing therapies for complex gene editing, including gene elimination, insertion and excision.